Nature Search

Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II)

D Rischin
V Ling
Research01 Aug 1996
British Journal of Cancer

Volume: 74, P: 590-596
A phase II trial of paclitaxel and epirubicin in advanced breast cancer

D Rischin
J Smith
J McKendrick
ResearchOpen Access25 Jul 2000
British Journal of Cancer

Volume: 83, P: 438-442
Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

There is high prevalence of whole genome duplication (WGD) in high grade serous ovarian cancer. Here, the authors compare tumours with and without WGD and find that those that acquired WGD early during tumour evolution are associated with worse survival and have the lowest expression of MHC-II.

Nikki L. Burdett
Madelynne O. Willis
Elizabeth L. Christie
ResearchOpen Access18 Jul 2024
Nature Communications

Volume: 15, P: 1-13
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A region on chromosome 19p13 is associated with the risk of developing ovarian and breast cancer. Here, the authors genotyped SNPs in this region in thousands of breast and ovarian cancer patients and identified SNPs associated with three genes, which were analysed with functional studies.

Kate Lawrenson
Siddhartha Kar
Simon A. Gayther
ResearchOpen Access07 Sept 2016
Nature Communications

Volume: 7, P: 1-22
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study

F Doz
J C Gentet
J Catalin
ResearchOpen Access27 Feb 2001
British Journal of Cancer

Volume: 84, P: 604-610
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

A Riccardi
P Pugliese
C Tinelli
ResearchOpen Access17 Jul 2001
British Journal of Cancer

Volume: 85, P: 141-146
A phase I study of the nitroimidazole hypoxia marker SR4554 using ¹⁹F magnetic resonance spectroscopy

C P Lee
G S Payne
I Judson
ResearchOpen Access24 Nov 2009
British Journal of Cancer

Volume: 101, P: 1860-1868
Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

Genome-wide association studies have identified regions which confer risk of high-grade serous epithelial ovarian cancer. Here the authors use expression quantitative train locus analysis to identify candidate genes and functionally characterise them, identifying a role for HOXD9 in ovarian cancer.

Kate Lawrenson
Qiyuan Li
Matthew L. Freedman
ResearchOpen Access22 Sept 2015
Nature Communications

Volume: 6, P: 1-14
Frequency and prognostic significance of p16^INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma

R J Young
D Urban
D Rischin
ResearchOpen Access17 Feb 2015
British Journal of Cancer

Volume: 112, P: 1098-1104
Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

Andres M. Arias Lorza
Harshan Ravi
Natarajan Raghunand
ResearchOpen Access02 Sept 2020
Scientific Reports

Volume: 10, P: 1-12
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC.

Olga Kondrashova
Monique Topp
Clare L. Scott
ResearchOpen Access28 Sept 2018
Nature Communications

Volume: 9, P: 1-16
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer

H M Prince
J Gardyn
G C Toner
Research26 Feb 1999
Bone Marrow Transplantation

Volume: 23, P: 427-435
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

A Wardley
N Davidson
D Cameron
ResearchOpen Access03 May 2005
British Journal of Cancer

Volume: 92, P: 1869-1876
Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma

G Halec
D Holzinger
M Pawlita
ResearchOpen Access18 Jun 2013
British Journal of Cancer

Volume: 109, P: 172-183
Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients

M J Dooley
S Singh
D Rischin
ResearchOpen Access02 Mar 2004
British Journal of Cancer

Volume: 90, P: 991-995
Docetaxel effectively mobilizes peripheral blood CD34⁺ cells

HM Prince
GC Toner
D Rischin
Research31 Aug 2000
Bone Marrow Transplantation

Volume: 26, P: 483-487
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang
Dane Cheasley
Kylie L. Gorringe
Research28 Jul 2020
Modern Pathology

Volume: 34, P: 194-206
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

HM Prince
D Rischin
P Briggs
Research20 Nov 2000
Bone Marrow Transplantation

Volume: 26, P: 955-961
Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole

N C Dhani
S Serra
D W Hedley
ResearchOpen Access01 Sept 2015
British Journal of Cancer

Volume: 113, P: 864-871
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature

L Mileshkin
HM Prince
A Zimet
Research20 Apr 2001
Bone Marrow Transplantation

Volume: 27, P: 559-563
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

Nikki L. Burdett
Madelynne O. Willis
Elizabeth L. Christie
ResearchOpen Access11 Dec 2023
Scientific Reports

Volume: 13, P: 1-10
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial

S Loi
S Y K Ngan
D Rischin
ResearchOpen Access08 Feb 2005
British Journal of Cancer

Volume: 92, P: 655-661
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

Bo Gao
Amanda Russell
Anna deFazio
ResearchOpen Access09 May 2014
Scientific Reports

Volume: 4, P: 1-9
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

X F Hu
A Slater
J Zalcberg
ResearchOpen Access29 Jan 1999
British Journal of Cancer

Volume: 79, P: 831-837
A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC

M Michael
A Wirth
A D Milner
ResearchOpen Access06 Sept 2005
British Journal of Cancer

Volume: 93, P: 652-661
Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

F L Day
T Leong
M Michael
ResearchOpen Access14 Dec 2010
British Journal of Cancer

Volume: 104, P: 265-271
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

A K Nowak
M J Byrne
B W S Robinson
ResearchOpen Access27 Aug 2002
British Journal of Cancer

Volume: 87, P: 491-496
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium

C L Pearce
A M Near
G Chenevix-Trench
ResearchOpen Access06 Jan 2009
British Journal of Cancer

Volume: 100, P: 412-420

Search

Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

A phase I study of the nitroimidazole hypoxia marker SR4554 using ¹⁹F magnetic resonance spectroscopy

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

Frequency and prognostic significance of p16^INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma

Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma

Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients

Docetaxel effectively mobilizes peripheral blood CD34⁺ cells

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole

Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium

Search

Quick links

Search

Filter By:

Search

Quick links